02722nam 2200613 a 450 991082876930332120220106004854.01-118-68218-11-299-46883-71-118-68220-3(CKB)2670000000342126(EBL)1165087(OCoLC)836400729(SSID)ssj0000856518(PQKBManifestationID)12382870(PQKBTitleCode)TC0000856518(PQKBWorkID)10807891(PQKB)10565313(MiAaPQ)EBC1165087(Au-PeEL)EBL1165087(CaPaEBR)ebr10684967(CaONFJC)MIL478133(EXLCZ)99267000000034212620110124d2011 uy 0engur|n|---|||||txtccrNew mechanisms in glucose control[electronic resource] /Anthony H. Barnett, Jenny GriceChichester, West Sussex Wiley-Blackwell20111 online resource (74 p.)Description based upon print version of record.1-118-68219-X 1-4443-3461-1 Includes bibliographical references and index.Epidemiology and pathogenesis of type 2 diabetes -- Overview of current diabetes management -- The incretin system -- The incretin mimetics -- Dipeptidyl peptidase-4 inhibitors -- Sodium-glucose cotransporter-2 inhibitors -- Pipeline diabetes therapies -- Bariatric surgery for the treatment of type 2 diabetes -- Organization of diabetes care.New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabeteType 2 diabetesHypoglycemic agentsObesitySurgeryType 2 diabetes.Hypoglycemic agents.ObesitySurgery.616.4/624Barnett A. H(Anthony H.),1951-1621466Grice Jenny1708282MiAaPQMiAaPQMiAaPQBOOK9910828769303321New mechanisms in glucose control4097194UNINA